FURVENT: Phase 3 trial of firmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations (FURMO-004).
Spira A, Cho BC, Felip E, Garon EB, Goto K, Johnson M, Leighl N, Passaro A, Planchard D, Popat S, Yang JC, Lu X, Jiang Y, Huang J, Lam M, Kowanetz M, Wang S, Le J, Hsu JY, Zhou CC.
Spira A, et al. Among authors: yang jc.
Lung Cancer. 2024 Dec 28;199:108066. doi: 10.1016/j.lungcan.2024.108066. Online ahead of print.
Lung Cancer. 2024.
PMID: 39764938
Review.
No abstract available.